| BMS-207147 |
| 4-[2-[(2R,3R)-3-(2,4-Difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile |
| (CAS 182760-06-1) |
 |
| Description： |
Ravuconazole (BMS-207147 and ER-30346) is a potent triazole antifungal, being developed by Bristol-Myers Squibb, that is currently in phase I/II clinical trials.[1] The drug has a shown to have a similar spectrum of activity to voriconazole, with an increased half-life.[2] However, ravuconazole has limited activity against species of Fusarium, Scedosporium, and Zygomycetes.[3][4]
|
| Product No. |
KT00193 |
| Product Name |
BMS-207147 |
| Synonyms |
|
| Formal Name |
4-[2-[(2R,3R)-3-(2,4-Difluorophenyl)-3-hydroxy-4-(1,2,4-triazol-1-yl)butan-2-yl]-1,3-thiazol-4-yl]benzonitrile |
| CAS Number |
182760-06-1 |
| Molecular Formula |
C22H17F2N5OS |
| Formula Weight |
437.465 |
| Formulation |
A crystalline solid |
| Purity |
98%min |
| Stability |
2 years |
| Storage |
-20°C |
| Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
| Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
| Price & Availability |
In Stock. Price Negotiated. |
|
| Related Products： |
E-64
AEBSF HCl
Glimepiride
Linagliptin
Alogliptin
MG-132
|
|
